Viewing Study NCT03823859


Ignite Creation Date: 2025-12-24 @ 2:47 PM
Ignite Modification Date: 2026-03-15 @ 6:05 PM
Study NCT ID: NCT03823859
Status: COMPLETED
Last Update Posted: 2022-05-17
First Post: 2019-01-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Metabolomics of Thyroid Hormones
Sponsor: University Hospital, Basel, Switzerland
Organization:

Study Overview

Official Title: Metabolomics of Thyroid Hormones
Status: COMPLETED
Status Verified Date: 2022-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MATcH
Brief Summary: The aim of this study is to develop a metabolome signature of thyroid hormone status. The metabolome signature could be useful in diagnosis and treatment of thyroid dysfunction diseases, especially in cases where TSH cannot be reliably used.
Detailed Description: Primary Hypothyroidism is a frequent endocrine disorder, where the thyroid gland does not produce sufficient amounts of thyroid hormones. The substitution therapy is guided by measurement of the pituitary gland hormone thyrotropin (TSH). Patients with central hypothyroidism in whom pituitary insufficiency leads to hypothyroidism, TSH cannot be used to guide therapy. So far there are no reliable methods for therapy control in patients with central hypothyroidism.

The measurement of small endogenous metabolites might give investigators a metabolomics profile. This could help to discriminate between euthyroid, hypothyroid and hyperthyroid state and therefore could be used for diagnosis and therapy control of thyroid dysfunction diseases.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: